Review



4 × 180 k cytosureisca v2 oligonucleotide microarray platform  (Oxford Gene Technology)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Oxford Gene Technology 4 × 180 k cytosureisca v2 oligonucleotide microarray platform
    Number of activities by type prompted by sequential testing scenario: non-diagnostic CMA followed by diagnostic and non-diagnostic WGS results (n = 93). CMA chromosomal <t>microarray</t> analysis, WGS whole genome sequencing. 1. Lab tests may include genetic, biochemical and hematogy tests. Allied health may include audiology, dietetics/nutrition, occupational therapy and physiotherapy, spech and language therapy and psychology. Other activities may include electrocardiogram (ECG) electroencephalogram (EEG), Holter monitor, visual evoked potential (VEP), electromyography (EMG), Electroretinography (ERG), evoked potential, monitoring and surveillance and other. 2. The number of times a given test was implemented was included in the activity count. 3. Activities that are standard after CMA or WGS tests, validation testing (Sanger sequencing) and genetic counselling were not included
    4 × 180 K Cytosureisca V2 Oligonucleotide Microarray Platform, supplied by Oxford Gene Technology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/4+%C3%97+180+k+cytosureisca+v2+oligonucleotide+microarray+platform/4+%C3%97+180+k+cytosureisca+v2+oligonucleotide+microarray+platform/pmc05865210-110-10-15
    Average 90 stars, based on 1 article reviews
    4 × 180 k cytosureisca v2 oligonucleotide microarray platform - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Care and cost consequences of pediatric whole genome sequencing compared to chromosome microarray"

    Article Title: Care and cost consequences of pediatric whole genome sequencing compared to chromosome microarray

    Journal: European Journal of Human Genetics

    doi: 10.1038/s41431-017-0020-3

    Number of activities by type prompted by sequential testing scenario: non-diagnostic CMA followed by diagnostic and non-diagnostic WGS results (n = 93). CMA chromosomal microarray analysis, WGS whole genome sequencing. 1. Lab tests may include genetic, biochemical and hematogy tests. Allied health may include audiology, dietetics/nutrition, occupational therapy and physiotherapy, spech and language therapy and psychology. Other activities may include electrocardiogram (ECG) electroencephalogram (EEG), Holter monitor, visual evoked potential (VEP), electromyography (EMG), Electroretinography (ERG), evoked potential, monitoring and surveillance and other. 2. The number of times a given test was implemented was included in the activity count. 3. Activities that are standard after CMA or WGS tests, validation testing (Sanger sequencing) and genetic counselling were not included
    Figure Legend Snippet: Number of activities by type prompted by sequential testing scenario: non-diagnostic CMA followed by diagnostic and non-diagnostic WGS results (n = 93). CMA chromosomal microarray analysis, WGS whole genome sequencing. 1. Lab tests may include genetic, biochemical and hematogy tests. Allied health may include audiology, dietetics/nutrition, occupational therapy and physiotherapy, spech and language therapy and psychology. Other activities may include electrocardiogram (ECG) electroencephalogram (EEG), Holter monitor, visual evoked potential (VEP), electromyography (EMG), Electroretinography (ERG), evoked potential, monitoring and surveillance and other. 2. The number of times a given test was implemented was included in the activity count. 3. Activities that are standard after CMA or WGS tests, validation testing (Sanger sequencing) and genetic counselling were not included

    Techniques Used: Diagnostic Assay, Microarray, Sequencing, Activity Assay, Biomarker Discovery

    Related Articles

    Microarray:

    Article Title: Care and cost consequences of pediatric whole genome sequencing compared to chromosome microarray
    Article Snippet: .. CMA was undertaken using the 4 × 180 K CytoSureISCA v2 oligonucleotide microarray platform (Oxford Gene Technology, Oxford, UK), the standard diagnostic service offered by SickKids Clinical Laboratory Improvement Amendments (CLIA)-certified diagnostic laboratory. ..

    Article Title: Care and cost consequences of pediatric whole genome sequencing compared to chromosome microarray
    Article Snippet: .. Platforms CMA was undertaken using the 4 × 180 K CytoSureISCA v2 oligonucleotide microarray platform (Oxford Gene Technology, Oxford, UK), the standard diagnostic service offered by SickKids Clinical Laboratory Improvement Amendments (CLIA)-certified diagnostic laboratory. ..

    Diagnostic Assay:

    Article Title: Care and cost consequences of pediatric whole genome sequencing compared to chromosome microarray
    Article Snippet: .. CMA was undertaken using the 4 × 180 K CytoSureISCA v2 oligonucleotide microarray platform (Oxford Gene Technology, Oxford, UK), the standard diagnostic service offered by SickKids Clinical Laboratory Improvement Amendments (CLIA)-certified diagnostic laboratory. ..

    Article Title: Care and cost consequences of pediatric whole genome sequencing compared to chromosome microarray
    Article Snippet: .. Platforms CMA was undertaken using the 4 × 180 K CytoSureISCA v2 oligonucleotide microarray platform (Oxford Gene Technology, Oxford, UK), the standard diagnostic service offered by SickKids Clinical Laboratory Improvement Amendments (CLIA)-certified diagnostic laboratory. ..



    Similar Products

    4 × 180 k cytosureisca v2 oligonucleotide microarray platform  (Oxford Gene Technology)
    90
    Oxford Gene Technology 4 × 180 k cytosureisca v2 oligonucleotide microarray platform
    Number of activities by type prompted by sequential testing scenario: non-diagnostic CMA followed by diagnostic and non-diagnostic WGS results (n = 93). CMA chromosomal <t>microarray</t> analysis, WGS whole genome sequencing. 1. Lab tests may include genetic, biochemical and hematogy tests. Allied health may include audiology, dietetics/nutrition, occupational therapy and physiotherapy, spech and language therapy and psychology. Other activities may include electrocardiogram (ECG) electroencephalogram (EEG), Holter monitor, visual evoked potential (VEP), electromyography (EMG), Electroretinography (ERG), evoked potential, monitoring and surveillance and other. 2. The number of times a given test was implemented was included in the activity count. 3. Activities that are standard after CMA or WGS tests, validation testing (Sanger sequencing) and genetic counselling were not included
    4 × 180 K Cytosureisca V2 Oligonucleotide Microarray Platform, supplied by Oxford Gene Technology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/4+%C3%97+180+k+cytosureisca+v2+oligonucleotide+microarray+platform/4+%C3%97+180+k+cytosureisca+v2+oligonucleotide+microarray+platform/pmc05865210-110-10-15
    Average 90 stars, based on 1 article reviews
    4 × 180 k cytosureisca v2 oligonucleotide microarray platform - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Number of activities by type prompted by sequential testing scenario: non-diagnostic CMA followed by diagnostic and non-diagnostic WGS results (n = 93). CMA chromosomal microarray analysis, WGS whole genome sequencing. 1. Lab tests may include genetic, biochemical and hematogy tests. Allied health may include audiology, dietetics/nutrition, occupational therapy and physiotherapy, spech and language therapy and psychology. Other activities may include electrocardiogram (ECG) electroencephalogram (EEG), Holter monitor, visual evoked potential (VEP), electromyography (EMG), Electroretinography (ERG), evoked potential, monitoring and surveillance and other. 2. The number of times a given test was implemented was included in the activity count. 3. Activities that are standard after CMA or WGS tests, validation testing (Sanger sequencing) and genetic counselling were not included

    Journal: European Journal of Human Genetics

    Article Title: Care and cost consequences of pediatric whole genome sequencing compared to chromosome microarray

    doi: 10.1038/s41431-017-0020-3

    Figure Lengend Snippet: Number of activities by type prompted by sequential testing scenario: non-diagnostic CMA followed by diagnostic and non-diagnostic WGS results (n = 93). CMA chromosomal microarray analysis, WGS whole genome sequencing. 1. Lab tests may include genetic, biochemical and hematogy tests. Allied health may include audiology, dietetics/nutrition, occupational therapy and physiotherapy, spech and language therapy and psychology. Other activities may include electrocardiogram (ECG) electroencephalogram (EEG), Holter monitor, visual evoked potential (VEP), electromyography (EMG), Electroretinography (ERG), evoked potential, monitoring and surveillance and other. 2. The number of times a given test was implemented was included in the activity count. 3. Activities that are standard after CMA or WGS tests, validation testing (Sanger sequencing) and genetic counselling were not included

    Article Snippet: Platforms CMA was undertaken using the 4 × 180 K CytoSureISCA v2 oligonucleotide microarray platform (Oxford Gene Technology, Oxford, UK), the standard diagnostic service offered by SickKids Clinical Laboratory Improvement Amendments (CLIA)-certified diagnostic laboratory.

    Techniques: Diagnostic Assay, Microarray, Sequencing, Activity Assay, Biomarker Discovery